FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W160176238> ?p ?o ?g. }

• W160176238 endingPage "1207" @default.
• W160176238 startingPage "1199" @default.
• W160176238 abstract "The aim of this study was to evaluate clinical and economic outcomes for subjects receiving zotarolimus-eluting (ZES) (n = 323) versus sirolimus-eluting stents (SES) (n = 113) in the ENDEAVOR III (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) clinical trial. Although previous clinical trials have evaluated long-term clinical outcome for drug-eluting stents, none considered their economic implications. We analyzed case report form information with quality-of-life adjustment and Medicare cost weights applied from secondary sources; compared differences in clinical outcomes, quality-adjusted survival, medical resource use, and medical costs; and evaluated cost-effectiveness through 3-year follow-up. The use of ZES versus SES reduced the 3-year rates/100 subjects of death or myocardial infarction (3.9 vs. 10.8; difference, −6.9; 95% confidence interval [CI]: −13.0 to 0.8; p = 0.028), with no difference in target vessel revascularization rates (17.9 vs. 12.2; difference, 5.7; 95% CI: −3.7 to 15.1; p = 0.23) but greater use of coronary artery bypass graft (CABG) surgery (3.5 vs. 0.0; difference 3.5; 95% CI: 1.3 to 5.7; p = 0.002). After discounting at 3% per annum, total medical costs for ZES versus SES were similar ($23,353 vs. $21,657; difference, $1,696; 95% CI: −$1,089 to $4,482, p = 0.23), and the 3-year cost-effectiveness ratio was $57,002/quality-adjusted life year. Despite a reduction in death or myocardial infarction and no difference in total revascularizations, medical costs were not decreased due to increased CABG repeat revascularization procedures for subjects receiving ZES versus SES. If future trials observe similar differences, improved safety with no difference in medical costs, the use of ZES versus SES will be a clinically and economically attractive treatment strategy. (The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial [ENDEAVOR III]; NCT00217256)" @default.
• W160176238 created "2016-06-24" @default.
• W160176238 creator A5000229386 @default.
• W160176238 creator A5041084808 @default.
• W160176238 creator A5065425489 @default.
• W160176238 creator A5071472368 @default.
• W160176238 creator A5071968251 @default.
• W160176238 creator A5080197453 @default.
• W160176238 creator A5081743465 @default.
• W160176238 creator A5088375340 @default.
• W160176238 creator A5090503044 @default.
• W160176238 date "2009-12-01" @default.
• W160176238 modified "2023-09-29" @default.
• W160176238 title "Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent" @default.
• W160176238 cites W105018345 @default.
• W160176238 cites W1278305590 @default.
• W160176238 cites W156679034 @default.
• W160176238 cites W1774610061 @default.
• W160176238 cites W1968106809 @default.
• W160176238 cites W1976713371 @default.
• W160176238 cites W1978136073 @default.
• W160176238 cites W1989440763 @default.
• W160176238 cites W1997207240 @default.
• W160176238 cites W1998792752 @default.
• W160176238 cites W2002736917 @default.
• W160176238 cites W2014656782 @default.
• W160176238 cites W2019199009 @default.
• W160176238 cites W2022818171 @default.
• W160176238 cites W2032456534 @default.
• W160176238 cites W2034456357 @default.
• W160176238 cites W2045291273 @default.
• W160176238 cites W2060153501 @default.
• W160176238 cites W2077883810 @default.
• W160176238 cites W2078113728 @default.
• W160176238 cites W2083630382 @default.
• W160176238 cites W2106334028 @default.
• W160176238 cites W2120050284 @default.
• W160176238 cites W2140752328 @default.
• W160176238 cites W2141117188 @default.
• W160176238 cites W2141165366 @default.
• W160176238 cites W2156613502 @default.
• W160176238 cites W2613557783 @default.
• W160176238 doi "https://doi.org/10.1016/j.jcin.2009.10.009" @default.
• W160176238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20129546" @default.
• W160176238 hasPublicationYear "2009" @default.
• W160176238 type Work @default.
• W160176238 sameAs 160176238 @default.
• W160176238 citedByCount "53" @default.
• W160176238 countsByYear W1601762382012 @default.
• W160176238 countsByYear W1601762382013 @default.
• W160176238 countsByYear W1601762382014 @default.
• W160176238 countsByYear W1601762382015 @default.
• W160176238 countsByYear W1601762382016 @default.
• W160176238 countsByYear W1601762382017 @default.
• W160176238 countsByYear W1601762382018 @default.
• W160176238 countsByYear W1601762382019 @default.
• W160176238 countsByYear W1601762382021 @default.
• W160176238 countsByYear W1601762382022 @default.
• W160176238 crossrefType "journal-article" @default.
• W160176238 hasAuthorship W160176238A5000229386 @default.
• W160176238 hasAuthorship W160176238A5041084808 @default.
• W160176238 hasAuthorship W160176238A5065425489 @default.
• W160176238 hasAuthorship W160176238A5071472368 @default.
• W160176238 hasAuthorship W160176238A5071968251 @default.
• W160176238 hasAuthorship W160176238A5080197453 @default.
• W160176238 hasAuthorship W160176238A5081743465 @default.
• W160176238 hasAuthorship W160176238A5088375340 @default.
• W160176238 hasAuthorship W160176238A5090503044 @default.
• W160176238 hasBestOaLocation W1601762381 @default.
• W160176238 hasConcept C126322002 @default.
• W160176238 hasConcept C141071460 @default.
• W160176238 hasConcept C164705383 @default.
• W160176238 hasConcept C2777546689 @default.
• W160176238 hasConcept C2777921159 @default.
• W160176238 hasConcept C2778213512 @default.
• W160176238 hasConcept C2778283817 @default.
• W160176238 hasConcept C2778583881 @default.
• W160176238 hasConcept C2780797203 @default.
• W160176238 hasConcept C44249647 @default.
• W160176238 hasConcept C500558357 @default.
• W160176238 hasConcept C71924100 @default.
• W160176238 hasConceptScore W160176238C126322002 @default.
• W160176238 hasConceptScore W160176238C141071460 @default.
• W160176238 hasConceptScore W160176238C164705383 @default.
• W160176238 hasConceptScore W160176238C2777546689 @default.
• W160176238 hasConceptScore W160176238C2777921159 @default.
• W160176238 hasConceptScore W160176238C2778213512 @default.
• W160176238 hasConceptScore W160176238C2778283817 @default.
• W160176238 hasConceptScore W160176238C2778583881 @default.
• W160176238 hasConceptScore W160176238C2780797203 @default.
• W160176238 hasConceptScore W160176238C44249647 @default.
• W160176238 hasConceptScore W160176238C500558357 @default.
• W160176238 hasConceptScore W160176238C71924100 @default.
• W160176238 hasFunder F4320307758 @default.
• W160176238 hasFunder F4320307813 @default.
• W160176238 hasIssue "12" @default.
• W160176238 hasLocation W1601762381 @default.
• W160176238 hasLocation W1601762382 @default.

• next